The Manufacturers Life Insurance Company Purchases 456 Shares of Simulations Plus, Inc. (NASDAQ:SLP)

The Manufacturers Life Insurance Company increased its stake in Simulations Plus, Inc. (NASDAQ:SLP) by 7.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,391 shares of the technology company’s stock after buying an additional 456 shares during the period. The Manufacturers Life Insurance Company’s holdings in Simulations Plus were worth $311,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. Azzad Asset Management Inc. ADV increased its stake in Simulations Plus by 3.6% in the 2nd quarter. Azzad Asset Management Inc. ADV now owns 8,007 shares of the technology company’s stock worth $389,000 after buying an additional 280 shares during the period. InTrack Investment Management Inc increased its stake in Simulations Plus by 1.1% in the 2nd quarter. InTrack Investment Management Inc now owns 31,665 shares of the technology company’s stock worth $1,540,000 after buying an additional 330 shares during the period. Chatham Capital Group Inc. increased its stake in Simulations Plus by 1.3% in the 2nd quarter. Chatham Capital Group Inc. now owns 34,554 shares of the technology company’s stock worth $1,680,000 after buying an additional 450 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Simulations Plus by 5.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,048 shares of the technology company’s stock worth $414,000 after buying an additional 562 shares during the period. Finally, Tributary Capital Management LLC increased its stake in Simulations Plus by 0.4% in the 2nd quarter. Tributary Capital Management LLC now owns 210,445 shares of the technology company’s stock worth $10,232,000 after buying an additional 768 shares during the period. Hedge funds and other institutional investors own 78.08% of the company’s stock.

Insider Activity

In other news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $35.18, for a total value of $703,600.00. Following the sale, the director now directly owns 3,501,592 shares in the company, valued at approximately $123,186,006.56. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have sold 60,750 shares of company stock worth $2,145,055. Corporate insiders own 20.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on SLP shares. Craig Hallum reissued a “buy” rating and set a $56.00 target price on shares of Simulations Plus in a research report on Wednesday, July 3rd. William Blair reissued an “outperform” rating on shares of Simulations Plus in a research report on Thursday, September 12th. KeyCorp started coverage on shares of Simulations Plus in a research report on Monday, July 29th. They set an “overweight” rating and a $47.00 target price on the stock. Finally, JMP Securities started coverage on shares of Simulations Plus in a research report on Tuesday, July 16th. They set a “market perform” rating on the stock. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $56.00.

Simulations Plus Stock Performance

NASDAQ:SLP opened at $33.29 on Friday. Simulations Plus, Inc. has a fifty-two week low of $29.37 and a fifty-two week high of $51.22. The stock has a market capitalization of $666.13 million, a P/E ratio of 69.35 and a beta of 0.69. The company’s 50-day simple moving average is $33.49 and its 200-day simple moving average is $41.07.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.